Retrophin Inc. (NASDAQ:RTRX)’s share price traded up 1.4% during mid-day trading on Friday . The stock traded as high as $18.90 and last traded at $18.35, with a volume of 98,019 shares changing hands. The stock had previously closed at $18.09.

Several equities analysts have recently issued reports on the company. JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research note on Saturday, July 9th. BMO Capital Markets reaffirmed an “outperform” rating and set a $25.00 price target on shares of Retrophin in a research note on Friday. Zacks Investment Research raised Retrophin from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Saturday, April 23rd. Finally, Leerink Swann reaffirmed a “buy” rating and set a $27.00 price target on shares of Retrophin in a research note on Monday, June 27th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Retrophin currently has a consensus rating of “Buy” and a consensus target price of $23.60.

The firm’s 50-day moving average is $17.91 and its 200-day moving average is $15.97. The company has a market cap of $677.77 million and a PE ratio of 9.62.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.36. During the same quarter in the prior year, the business posted ($0.18) EPS. The firm had revenue of $29 million for the quarter, compared to analyst estimates of $31 million. The firm’s quarterly revenue was up 66.7% compared to the same quarter last year. On average, equities research analysts expect that Retrophin Inc. will post $0.08 EPS for the current fiscal year.

In related news, EVP Alvin Shih sold 8,750 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $17.75, for a total transaction of $155,312.50. Following the sale, the executive vice president now owns 167,084 shares in the company, valued at $2,965,741. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Several hedge funds recently made changes to their positions in RTRX. California State Teachers Retirement System raised its stake in shares of Retrophin by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 64,781 shares of the biopharmaceutical company’s stock valued at $1,250,000 after buying an additional 1,129 shares during the period. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Retrophin by 1,449.5% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 91,421 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 85,521 shares during the period. Turner Investments L.P. raised its stake in shares of Retrophin by 61.6% in the fourth quarter. Turner Investments L.P. now owns 384,760 shares of the biopharmaceutical company’s stock valued at $7,422,000 after buying an additional 146,720 shares during the period. Finally, Tekla Capital Management LLC bought a new stake in shares of Retrophin during the fourth quarter valued at about $6,365,000.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.